Citadel Advisors’s Gain Therapeutics GANX Stock Holding History

Citadel Advisors’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-31,400	Closed	-$60.9K	–	14097
2026 Q1	$60.9K	Buy	31,400 +5,300	+20%	+$11.5K	﹤0.01%	12327
2025 Q4	$84K	Buy	+26,100	New	+$69.7K	﹤0.01%	11764
2025 Q2	–	Sell	-8,700	Closed	-$16.6K	–	13409
2025 Q1	$16.6K	Sell	8,700 -1,900	-18%	-$4.21K	﹤0.01%	13273
2024 Q4	$22.9K	Buy	+10,600	New	+$21.3K	﹤0.01%	13090
2024 Q2	–	Sell	-2,500	Closed	-$9.43K	–	14672
2024 Q1	$9.43K	Sell	2,500 -4,500	-64%	-$18.7K	﹤0.01%	13500
2023 Q4	$22.9K	Buy	7,000 +2,900	+71%	+$8.06K	﹤0.01%	12511
2023 Q3	$13.2K	Buy	+4,100	New	+$15.5K	﹤0.01%	12932
2023 Q2	–	Sell	-100	Closed	-$482	–	14652
2023 Q1	$482	Buy	+100	New	+$409	﹤0.01%	14489

Other funds holding GANX

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

PCM

Potomac Capital Management New York $147M AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

DCM

DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Citadel Advisors's GANX Position: Q2 2026 in Review

Citadel Advisors increased its Gain Therapeutics (GANX) stake by 521% in Q2 2026, buying an estimated $239K and bringing the position to 154,524 shares worth $314K. The position accounts for ﹤0.01% of the portfolio, ranked #11018.

Citadel Advisors first reported a position in GANX in Q4 2021 and has held it in 12 quarters since. The position peaked at $661K in Q3 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

Citadel Advisors held 154,524 shares of Gain Therapeutics worth $314K as of Q2 2026.
Citadel Advisors bought 129,624 Gain Therapeutics shares in Q2 2026, an estimated $239K.
Gain Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11018 holding.
Citadel Advisors first reported a position in Gain Therapeutics in Q4 2021 and has held it in 12 quarters since.
Citadel Advisors's Gain Therapeutics position peaked at $661K in Q3 2025.
50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.